Gt biopharma to participate in-person at 34th annual roth conference, march 13-15, 2022

Brisbane, calif. , march 3, 2022 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® protein biologic technology platform, announced that dr. greg berk, president of r&d, chief medical officer and interim ceo, will participate in a fireside chat in-person at the 34th annual roth conference on tuesday march 15, 2022, at 8:30 am pt.
GTBP Ratings Summary
GTBP Quant Ranking